Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
FACS Fluorescence – Activated Cell Sorting
Applications include:
Immunophenotyping -4 color capability
Biomarker analysis
Cell viability (Annexin-PI)
Intracellular staining
Cell differentiation
Absolute cell counts
Calcium Flux
Cell cycle and ploidyROCK
Rho
FAK CrK
Pax PYK2
GTP Gα-O
GEFs
CDC42 Rac
MEKs
PAK MKKs
ASK1
JNK
P38 IP3R
PKC
BIMP1
BCL10
NFκB IκBs
P
IKKs
IκBsDegradation
Src
SOSGRB2SHC
RasGEFs
Raf1
MEKs
ERKs
PLC-β
DAG
NFκB
IKKs
PκB
IP3
Ca+2Ca+2
Ca+2
Calm
P
Caln
NFAT
NFAT
P
PI3K
Gβ Gγ
LARG
BRaf
MEKs
ERKs
cAMP
EPACPKA
PDZRhoGEF
Gα-1 GTP
Rap1
p115RhoGEF
RT
KS
CREB
Gα12/13
SRF
GTP
CREB
SRF ELK-1
c-Jun
c-Fos
STAT
NFκBNFAT
Gene Expression
Gα Gβ
© 2013 CDT all rights reserved
CON
LFU
ENCE
DIS
COVE
RY T
ECH
NO
LOG
IES
| TE
CHN
ICAL
BRI
EFTECHNICAL BRIEF:
FACSFluorescence - Activated
Cell SortingD I S C O V E R Y T E C H N O L O G I E S
FACS is an essential tool for in-depth cell analysis. With the capacity to simultaneously measure multiple parameters on hundreds of individual cells per second, FACS is a power-ful technology with a wide variety of applications in pharma-ceutical development. The Confluence Discovery Technologies (CDT) team has a wide range of experience in developing and validating FACS assays to suit many different requirements. Our highly trained and knowledgeable scientists will assist with experi-mental design to develop and validate assays to meet client-specified criteria. We also perform data analysis and interpretation of FACS data to enable our clients to obtain the best insights from large, complex data outputs. For assay design, development, validation, sample and data analysis, our experience in research and clinical devel-opment projects enables us to be an ideal FACS service part-ner.
Assay DevelopmentThe CDT team can advise on the most suitable assay proce-dure depending on the requirements of the client. Including:
•Sample type (e.g., whole blood, separated PBMC, serum, cultured cells)
•Stability of marker(s)/analyte(s) being measured
•Appropriate fluorochromes, dyes and conjugates to get the clearest data from your samples
•Incubation temperatures and periods most suited to the matrix and/or analytes
•Most suitable controls to monitor assay performance
•Appropriate QC checks on instrumentation to ensure cytometers are performing reproducibly
ROCK
Rho
FAK CrK
Pax PYK2
GTP Gα-O
GEFs
CDC42 Rac
MEKs
PAK MKKs
ASK1
JNK
P38 IP3R
PKC
BIMP1
BCL10
NFκB IκBs
P
IKKs
IκBsDegradation
Src
SOSGRB2SHC
RasGEFs
Raf1
MEKs
ERKs
PLC-β
DAG
NFκB
IKKs
PκB
IP3
Ca+2Ca+2
Ca+2
Calm
P
Caln
NFAT
NFAT
P
PI3K
Gβ Gγ
LARG
BRaf
MEKs
ERKs
cAMP
EPACPKA
PDZRhoGEF
Gα-1 GTP
Rap1
p115RhoGEF
RT
KS
CREB
Gα12/13
SRF
GTP
CREB
SRF ELK-1
c-Jun
c-Fos
STAT
NFκBNFAT
Gene Expression
Gα Gβ
© 2013 CDT all rights reserved
CDTv1.8.13
Confluence Discovery Technologies, Inc.4320 Forest Park Avenue
Saint Louis, MO 63108Phone: 314-932-4032 x305
Fax: 314-932-4038www.confluencediscovery.com
D I S C O V E R Y T E C H N O L O G I E S
CAPABILITIESD I S C O V E R Y T E C H N O L O G I E S
CON
LFU
ENCE
DIS
COVE
RY T
ECH
NO
LOG
IES
| CA
PABI
LITI
ES
Leaders in biochemistry and mechanistic enzymology, our senior team has access to a suite of capabilities and technologies enabling: • Drug:Target interaction • Enzyme:Inhibitor mechanisms • Direct binding kinetics • Compound mechanism of action
Con�uence o�ers a spectrum of cell and molecular biology capabilities: • Identi�cation of biologically important signal transduction pathways • Quantitation of e�cacy and selectivity • Understanding safety issues linked to pathways • De-convolution to isolate pathway nodes • Evaluation of multiple targets within the pathway • Identi�cation of key pathway point(s) for therapeutic intervention • Target validation, cloning, expression, and puri�cation • Custom assay development • High-throughput screening
Our team delivers when “OFF the SHELF” is not an option: • Assay development, optimization, and validation • Multiplex technology platforms and instrumentation • Complex data analysis • Specialty screens for preclinical technical application • Trouble shooting and problem solving
Our team provides clients with the expertise to: • Identify target, mechanism, and disease biomarkers • Select the appropriate biomarkers for a drug discovery program • Execute biomarker assay design, development, validation, and interpretation for pre-clinical and clinical studies • Seamless assay transfer from pre-clinical to clinical studies
Our medicinal and computational chemists are experts in designing and delivering novel chemical entities through: • Schrödinger® enabled computational drug design • High throughput hit prioritization • Chemical series prioritization • Structure activity relationship generation • Custom synthesis